Related Experiment Video
Updated: May 13, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis
Pragatheeshwar Thirunavukarasu1, Magesh Sathaiah, Michael C Gorry
1Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Abstract:
Oncolytic poxviruses have demonstrated initial promising results in patients with cancer in clinical trials, yet further improvements are needed. It has been shown that a single point mutation in the A34R gene resulted in the production of more total progeny virus and more extracellular enveloped virus (EEV), a form that can be immune-evasive and with enhanced spread. We have genetically engineered a new oncolytic poxvirus (designated vA34R) by incorporating this mutated A34R gene into a viral backbone (vvDD) which was designed for tumor-selective replication. This rationally designed virus can evade neutralization from antipoxvirus antibodies and is highly cytotoxic to cancer cells. It demonstrates improved spread and increased replication within the peritoneal cavity resulting in improved antitumor effects in a peritoneal carcinomatosis (PC) model of MC38 colon cancer. Impressively, after carrier cell-mediated delivery in the preimmunized host, vA34R displayed high replication in tumor nodules yet low accumulation in normal tissues thus enhancing the therapeutic index leading to 70% long-term cures. These results demonstrate that vA34R gains an enhanced therapeutic index for PC via immune evasion, increased spread, and production of more progeny virus. Thus, vA34R may be a potent oncolytic virus (OV) for patients with PC, even after prior exposure to vaccinia virus (VV).
Insights
A novel oncolytic poxvirus, vA34R, shows enhanced tumor-killing ability and immune evasion. This engineered virus offers improved cancer treatment, even in patients previously exposed to vaccinia virus.
Area of Science:
- Virology
- Oncology
- Immunotherapy
Background:
- Oncolytic poxviruses show promise in cancer therapy but require further optimization.
- A specific mutation in the A34R gene enhances viral progeny and extracellular enveloped virus (EEV) production, aiding immune evasion and spread.
Purpose of the Study:
- To engineer and evaluate a novel oncolytic poxvirus, vA34R, with enhanced therapeutic properties.
- To assess vA34R's efficacy in a preclinical model of peritoneal carcinomatosis (PC).
Main Methods:
- Genetic engineering of a poxvirus backbone (vvDD) with a mutated A34R gene to create vA34R.
- Evaluation of vA34R's replication, spread, cytotoxicity, and antitumor effects in MC38 colon cancer peritoneal carcinomatosis models.
- Assessment of vA34R's performance in pre-immunized hosts using carrier cell-mediated delivery.
Main Results:
- vA34R demonstrated tumor-selective replication, immune evasion from antipoxvirus antibodies, and high cytotoxicity to cancer cells.
- The virus exhibited improved spread and replication in the peritoneal cavity, leading to enhanced antitumor effects.
- In pre-immunized hosts, vA34R showed significant tumor replication with minimal accumulation in normal tissues, achieving 70% long-term cures.
Conclusions:
- The engineered oncolytic poxvirus vA34R possesses an enhanced therapeutic index for peritoneal carcinomatosis.
- vA34R's improved efficacy is attributed to immune evasion, increased viral spread, and augmented progeny production.
- vA34R represents a potent oncolytic virus for PC treatment, effective even in individuals with prior vaccinia virus exposure.
